Philosys Healthcare Obtains Export Approval for COVID-19 Antigen Rapid Test Kit
[Asia Economy Reporter Lim Jeong-su] Philosis Healthcare announced on the 25th that it has received export approval from the Ministry of Food and Drug Safety for the antigen rapid diagnostic kit ‘Gmate COVID-19 Ag’.
According to Philosis Healthcare, Gmate COVID-19 is simple to use as it measures saliva. Additionally, it is known to have high utility as results can be read and transmitted via an application (App).
This diagnostic kit is currently produced by the group affiliate Philosci and sold by Philosis Healthcare. Recently, it demonstrated 95% accuracy at a hospital under the Malaysian Ministry of Health, leading to an export contract with Malaysia.
With this export approval, full-scale exports of Gmate COVID-19 are expected to commence.
Hot Picks Today
"Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
- [Breaking] Prime Minister Kim Minseok Issues Public Statement on Samsung Electronics Strike: "Welcoming Resumption of Negotiations... Effectively the Last Opportunity"
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- Is It Really Like an Illness? "I Can't Wait to Go Again"—Over 1 Million Visited in Q1, Now 'Busanbyeong' Takes Hold [K-Holic]
A Philosis Healthcare official stated, "On the day of export approval, the 21st, 600,000 units were shipped, and approximately 1.5 million units are scheduled to be shipped by February," adding, "We are also negotiating export contracts with European countries such as Romania and Greece."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
